Cargando…

Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study

Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms are distressing for patients with quiescent Crohn’s disease (qCD) and worsen their quality of life. In the present study, we assessed the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the intestinal environment an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Toshihiko, Fukui, Hirokazu, Okugawa, Takuya, Nakanishi, Takashi, Mieno, Masatoshi, Nakai, Keisuke, Eda, Hirotsugu, Kitayama, Yoshitaka, Oshima, Tadayuki, Shinzaki, Shinichiro, Miwa, Hiroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219535/
https://www.ncbi.nlm.nih.gov/pubmed/37240476
http://dx.doi.org/10.3390/jcm12103368
_version_ 1785049032962342912
author Tomita, Toshihiko
Fukui, Hirokazu
Okugawa, Takuya
Nakanishi, Takashi
Mieno, Masatoshi
Nakai, Keisuke
Eda, Hirotsugu
Kitayama, Yoshitaka
Oshima, Tadayuki
Shinzaki, Shinichiro
Miwa, Hiroto
author_facet Tomita, Toshihiko
Fukui, Hirokazu
Okugawa, Takuya
Nakanishi, Takashi
Mieno, Masatoshi
Nakai, Keisuke
Eda, Hirotsugu
Kitayama, Yoshitaka
Oshima, Tadayuki
Shinzaki, Shinichiro
Miwa, Hiroto
author_sort Tomita, Toshihiko
collection PubMed
description Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms are distressing for patients with quiescent Crohn’s disease (qCD) and worsen their quality of life. In the present study, we assessed the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the intestinal environment and clinical features in patients with qCD. Eleven patients with qCD, who met the Rome III diagnostic criteria for IBS-D, received BBG9-1 (24 mg) orally three times daily for 4 weeks. Indices of the intestinal environment (fecal calprotectin level and gut microbiome) and clinical features (CD/IBS-related symptoms, quality of life and stool irregularities) were evaluated before and after treatment. Treatment with BBG9-1 tended to reduce the IBS severity index in the studied patients (p = 0.07). Among gastrointestinal symptoms, abdominal pain and dyspepsia tended to be improved by the BBG9-1 treatment (p = 0.07 and p = 0.07, respectively), and IBD-related QOL showed a significant improvement (p = 0.007). With regard to mental status, the patient anxiety score was significantly lower at the endpoint of BBG9-1 treatment than at the baseline (p = 0.03). Although BBG9-1 treatment did not affect the fecal calprotectin level, it suppressed the serum MCP-1 level significantly and increased the abundance of intestinal Bacteroides in the study patients. The probiotic BBG9-1 is able to improve IBD-related QOL with a reduction of anxiety score in patients with quiescent CD and IBS-D-like symptoms.
format Online
Article
Text
id pubmed-10219535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102195352023-05-27 Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study Tomita, Toshihiko Fukui, Hirokazu Okugawa, Takuya Nakanishi, Takashi Mieno, Masatoshi Nakai, Keisuke Eda, Hirotsugu Kitayama, Yoshitaka Oshima, Tadayuki Shinzaki, Shinichiro Miwa, Hiroto J Clin Med Article Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms are distressing for patients with quiescent Crohn’s disease (qCD) and worsen their quality of life. In the present study, we assessed the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the intestinal environment and clinical features in patients with qCD. Eleven patients with qCD, who met the Rome III diagnostic criteria for IBS-D, received BBG9-1 (24 mg) orally three times daily for 4 weeks. Indices of the intestinal environment (fecal calprotectin level and gut microbiome) and clinical features (CD/IBS-related symptoms, quality of life and stool irregularities) were evaluated before and after treatment. Treatment with BBG9-1 tended to reduce the IBS severity index in the studied patients (p = 0.07). Among gastrointestinal symptoms, abdominal pain and dyspepsia tended to be improved by the BBG9-1 treatment (p = 0.07 and p = 0.07, respectively), and IBD-related QOL showed a significant improvement (p = 0.007). With regard to mental status, the patient anxiety score was significantly lower at the endpoint of BBG9-1 treatment than at the baseline (p = 0.03). Although BBG9-1 treatment did not affect the fecal calprotectin level, it suppressed the serum MCP-1 level significantly and increased the abundance of intestinal Bacteroides in the study patients. The probiotic BBG9-1 is able to improve IBD-related QOL with a reduction of anxiety score in patients with quiescent CD and IBS-D-like symptoms. MDPI 2023-05-09 /pmc/articles/PMC10219535/ /pubmed/37240476 http://dx.doi.org/10.3390/jcm12103368 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tomita, Toshihiko
Fukui, Hirokazu
Okugawa, Takuya
Nakanishi, Takashi
Mieno, Masatoshi
Nakai, Keisuke
Eda, Hirotsugu
Kitayama, Yoshitaka
Oshima, Tadayuki
Shinzaki, Shinichiro
Miwa, Hiroto
Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title_full Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title_fullStr Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title_full_unstemmed Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title_short Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn’s Disease: A Prospective Pilot Study
title_sort effect of bifidobacterium bifidum g9-1 on the intestinal environment and diarrhea-predominant irritable bowel syndrome (ibs-d)-like symptoms in patients with quiescent crohn’s disease: a prospective pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219535/
https://www.ncbi.nlm.nih.gov/pubmed/37240476
http://dx.doi.org/10.3390/jcm12103368
work_keys_str_mv AT tomitatoshihiko effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT fukuihirokazu effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT okugawatakuya effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT nakanishitakashi effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT mienomasatoshi effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT nakaikeisuke effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT edahirotsugu effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT kitayamayoshitaka effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT oshimatadayuki effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT shinzakishinichiro effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy
AT miwahiroto effectofbifidobacteriumbifidumg91ontheintestinalenvironmentanddiarrheapredominantirritablebowelsyndromeibsdlikesymptomsinpatientswithquiescentcrohnsdiseaseaprospectivepilotstudy